Article
Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype.
Journal of affective disorders - 1 Jan 2018
Papolos Demitri, Frei Mark, Rossignol Daniel, Mattis Steven, Hernandez-Garcia Laura C, Teicher Martin H
Abstract excerpt
OBJECTIVES: Fear of Harm (FOH) is a pediatric onset phenotype of bipolar disorder (BD) characterized by BD plus treatment resistance, separation anxiety, aggressive obsessions, parasomnias, and thermal dysregulation. Intranasal ketamine (InK) in 12 youths with BD-FOH produced marked improvement during a two-week trial. Here we report on the open effectiveness and safety of InK in maintenance treatment of BD-FOH...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
